ASX Share rice
Wed 05 Aug 2020 - 11:58:pm (Sydney)

RGS Share Price

REGENEUS LTDRGSPharmaceuticals, Biotechnology & Life Sciences

RGS Company Information

Name:

Regeneus Ltd

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

2 Paddington Street Paddington NSW Australia 2021

Phone:

61 2 9499 8010

CEO & Exec. Director:

Mr. Leo Lee

Chief Scientific Officer & Exec. Director:

Prof. Graham Vesey

Chief Financial & Operations Officer:

Mr. John Bird

Head of R&D:

Dr. Charlotte Morgan

Company Sec. & Head of Corp. Affairs:

Ms. Sandra McIntosh

Company Overview:

Regeneus Ltd, a clinical-stage regenerative medicine company, engages in developing cell-based therapies for the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases. The company is developing its therapeutic products using its proprietary stem cell and immuno-oncology technology platforms. Its products under development for human health market include Progenza, a cell therapy that has completed Phase I clinical trial for the treatment of osteoarthritis and other musculoskeletal disorders; RGSH4K, a cancer vaccine, which is in Phase I clinical trial for the treatment of solid tumors; and Sygenus allogeneic cell secretion for use as a topical application for the treatment of acne and other inflammatory skin conditions, and wound healing. The company's animal health products comprise CryoShot, an allogeneic mesenchymal stem cell therapy for the treatment of canine osteoarthritis and other musculoskeletal disorders; and Kvax, an autologous cancer vaccine. Regeneus Ltd was founded in 2007 and is headquartered in Paddington, Australia.

RGS Share Price Information

Shares Issued:

277.82M

Market Capitalisation:

$31.95M

Revenue (TTM):

$1.45M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.029

Operating Margin (TTM):

$-3.30

Return On Assets (TTM):

$-1.21

Quarterly Revenue Growth (YOY):

-0.948

Gross Profit(TTM):

$1.47M

Diluted Earnings Per Share (TTM):

$-0.02

RGS CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-7,620

Change To Liabilities:

$1.28M

Total Cashflow From Investing Activities:

$-7,620

Net Borrowings:

$2.78M

Net Income:

$-6,024,600

Total Cash From Operating Activities:

$-3,608,496

Depreciation:

$269.14K

Change To Inventory:

$6.72K

Capital Expenditures:

$7.62K

RGS Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-6,024,600

Net Income:

$-6,024,600

Gross Profit:

$25.08K

Operating Income:

$-6,867,606

Interest Expense:

$402.80K

Total Revenue:

$25.08K

Total Operating Expenses:

$6.87M

RGS Balance Sheet

Balance Sheet Date:

2019-06-30

Total Liabilities:

$8.93M

Total Stockholder Equity:

$-6,386,495

Other Current Liabilities:

$3.56M

Total Assets:

$2.54M

Common Stock:

$31.08M

Other Current Assets:

$1.46M

Retained Earnings:

$-37,875,379

Other Liabilities:

$175.39K

Cash:

$255.46K

Total Current Liabilities:

$8.75M

Short-Term Debt:

$3.78M

Property - Plant & Equipment:

$153.45K

Net Tangible Assets:

$-6,386,495

Long-Term Investments:

$3.68K

Total Current Assets:

$2.38M

Net Receivables:

$1.85M

Short-Term Investments:

$157.12K

Inventory:

$8.62K

Accounts Payable:

$391.31K

Non Currrent Assets (Other):

$157.12K

Short-Term Investments:

$157.12

Non Current Liabilities Total:

$175.39K

RGS Share Price History

RGS News

16 Apr, 2020
Regeneus Ltd (ASX:RGS) shareholders should be happy to see the share price up 30% in the last month. But that can't...
17 Jan, 2020
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...